Please assess the completion status of the following clinical trial:

Trial Title: Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1. Documented histologically confirmed breast cancer with ER and/or PgR positive and HER2 negative status.~* 2. Locally advanced or metastatic breast cancer not deemed amenable to curative surgery or curative radiation therapy~* 3. HR+/HER2-~  1. HR+: ER+ or PR+ test before or up to 60 days after MBC diagnosis~ 2. HER2-: any HER2 negative test and the absence of a positive test (IHC positive 3+, FISH positive/amplified, Positive NOS) before or up to 60 days after MBC diagnosis~* 4. Female or male patients \> 18 years~* 5. Have received at least one dose of palbociclib~* 6. At least 2 document clinical visits~* 7. Treatment with palbociclib should have started from November 2017 to November 2019~* 8. Data from the clinical records should be available.~* 9. Patients must be able to understand and sign informed consent if alive.~Exclusion Criteria:~* 1. Previous treatment with hormonal therapy, targeted therapy or chemotherapy for metastatic disease. Previous anticancer treatment for early breast cancer are allowed.~* 2. Treatment with palbociclib in clinical trial or compassionate use programs~* 3. HER2 + (IHC 3+ or FISH +) tumors in the most recent or previous biopsies~* 4. HR negative tumors in the most recent biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).